(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

National Taiwan University Hospital, Taipei

NYU Langone Health, Laura and Isaac Perlmutter Cancer Center, New York

Icahn School of Medicine at Mount Sinai, New York

Institut Claudius Regaud (IUCT-O) - Cancer Comprehensive Center, Toulouse

Sarah Cannon Research Institute, Nashville

The University of Texas MD Anderson Cancer Center, Houston

University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles

UC San Diego Moores Cancer Center, La Jolla

UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange

Institut Gustave Roussy - DITEP, Villejuif

National Cancer Centre Singapore, Singapore

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston

Princess Margaret Cancer Centre, Toronto

National Cancer Center Hospital East, Kashiwa

Kanagawa Cancer Center, Yokohama

National Cancer Center Hospital, Chuo Ku

The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam

Seoul National University, Department of Internal Medicine, Seoul

Yonsei Cancer Center, Severance Hospital, Yonsei University, Seoul

Asan Medical Center, Department of Oncology, Seoul

Samsung Medical Center, Seoul

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Vall d'Hebron University Hospital, Oncology Department, Barcelona

The Royal Marsden NHS Foundation Trust, Sutton